|Dosage Form||Tablets (oral; 5 mg, 10 mg); Extended release tablets (oral; 11 mg)|
|Drug Class||Kinase inhibitors|
- Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
- Indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
- Indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients.
More on this drug: Clinical Trials
|Xeljanz (tofacitinib) Prescribing Information||2012||Pfizer Inc., New York, NY|
|Clinical review report: tofacitinib (xeljanz).||2019||CADTH|
|Pharmacoeconomic review report: tofacitinib (xeljanz).||2019||CADTH|
|Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.||2020||EULAR|
|AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis.||2020||Gastroenterology|
|AGA clinical practice guidelines on the management of mild to moderate ulcerative colitis.||2019||Gastroenterology|
|British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.||2019||BMJ|
|2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis.||2018||American College of Rheumatology|
|2017 American college of rheumatology/American association of hip and knee surgeons’ guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.||2017||Arthritis Care & Research|